Management of the respiratory distress symptom cluster in lung cancer: a randomised controlled feasibility trialCitation formats

  • External authors:
  • Mari Lloyd-Williams
  • Amelie Harle
  • June Warden
  • Jackie Ellis
  • Mark Pilling
  • Jemma Haines
  • Chris Bailey
  • Alexander Molassiotis

Standard

Management of the respiratory distress symptom cluster in lung cancer: a randomised controlled feasibility trial. / Yorke, Janelle; Lloyd-Williams, Mari; Smith, Jacky; Blackhall, Fiona; Harle, Amelie; Warden, June; Ellis, Jackie; Pilling, Mark; Haines, Jemma; Luker, Karen; Bailey, Chris; Molassiotis, Alexander.

In: Supportive Care in Cancer, Vol. 23, No. 11, 11.2015, p. 3373-3384.

Research output: Contribution to journalArticle

Harvard

Yorke, J, Lloyd-Williams, M, Smith, J, Blackhall, F, Harle, A, Warden, J, Ellis, J, Pilling, M, Haines, J, Luker, K, Bailey, C & Molassiotis, A 2015, 'Management of the respiratory distress symptom cluster in lung cancer: a randomised controlled feasibility trial', Supportive Care in Cancer, vol. 23, no. 11, pp. 3373-3384. https://doi.org/10.1007/s00520-015-2810-x

APA

Vancouver

Author

Yorke, Janelle ; Lloyd-Williams, Mari ; Smith, Jacky ; Blackhall, Fiona ; Harle, Amelie ; Warden, June ; Ellis, Jackie ; Pilling, Mark ; Haines, Jemma ; Luker, Karen ; Bailey, Chris ; Molassiotis, Alexander. / Management of the respiratory distress symptom cluster in lung cancer: a randomised controlled feasibility trial. In: Supportive Care in Cancer. 2015 ; Vol. 23, No. 11. pp. 3373-3384.

Bibtex

@article{44403bf3defc4982973046317d81432a,
title = "Management of the respiratory distress symptom cluster in lung cancer: a randomised controlled feasibility trial",
abstract = "Background: Breathlessness, cough and fatigue are distressing symptoms for patients with lung cancer. There is evidence that these three symptoms form a discreet symptom cluster. This study aimed to feasibility test a new non-pharmacological intervention for the management of the Respiratory Distress Symptom Cluster (breathlessness-cough-fatigue) in lung cancer. Method: This was a multi-centre, randomised controlled non-blinded parallel group feasibility trial. Eligible patients (patients with primary lung cancer and {\^a}€˜bothered{\^a}€™ by at least two of the three cluster symptoms) received usual care plus a multicomponent intervention delivered over two intervention training sessions and a follow-up telephone call or usual care only. Follow-up was for 12 weeks and end-points included: six numerical rating scales (NRS) for breathlessness severity; Dyspnoea-12; Manchester Cough in Lung Cancer scale (MCLS); FACT-Fatigue scale (FACT-F); Hospital Anxiety and Depression scale (HADS); Lung Cancer Symptom Scale (LCSS); and the EQ-5D-3L, collected at baseline, week-4 and week-12. Results: 107 patients were randomised over eight months; however six were removed from further analysis due to protocol violations (intervention group n=50 and control group n=51). Of the ineligible patients (n = 608), 29{\%} reported either not experiencing two or more symptoms or not being {\^a}€˜bothered{\^a}€™ by at least two symptoms. There was 29{\%} drop-out by week four and by week 12 a further two patients in the control group were lost to follow-up. A sample size calculation indicated that 122 patients per arm would be needed to detect a clinically important difference in the main outcome for breathlessness, cough and fatigue. Conclusions: The study has provided evidence of the feasibility and acceptability of a new intervention in the lung cancer population, and warrants a fully powered trial before we reach any conclusions. The follow-on trial will test the hypothesis that the intervention improves symptom cluster of breathlessness, cough and fatigue better than usual care alone. Full economic evaluation will be conducted in the main trial.",
keywords = "Breathlessness, Cough, Dyspnoea, Fatigue, Lung cancer, Non-pharmacological intervention, Respiratory symptoms, Self-management, Symptom cluster, Symptoms",
author = "Janelle Yorke and Mari Lloyd-Williams and Jacky Smith and Fiona Blackhall and Amelie Harle and June Warden and Jackie Ellis and Mark Pilling and Jemma Haines and Karen Luker and Chris Bailey and Alexander Molassiotis",
year = "2015",
month = "11",
doi = "10.1007/s00520-015-2810-x",
language = "English",
volume = "23",
pages = "3373--3384",
journal = "Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Nature",
number = "11",

}

RIS

TY - JOUR

T1 - Management of the respiratory distress symptom cluster in lung cancer: a randomised controlled feasibility trial

AU - Yorke, Janelle

AU - Lloyd-Williams, Mari

AU - Smith, Jacky

AU - Blackhall, Fiona

AU - Harle, Amelie

AU - Warden, June

AU - Ellis, Jackie

AU - Pilling, Mark

AU - Haines, Jemma

AU - Luker, Karen

AU - Bailey, Chris

AU - Molassiotis, Alexander

PY - 2015/11

Y1 - 2015/11

N2 - Background: Breathlessness, cough and fatigue are distressing symptoms for patients with lung cancer. There is evidence that these three symptoms form a discreet symptom cluster. This study aimed to feasibility test a new non-pharmacological intervention for the management of the Respiratory Distress Symptom Cluster (breathlessness-cough-fatigue) in lung cancer. Method: This was a multi-centre, randomised controlled non-blinded parallel group feasibility trial. Eligible patients (patients with primary lung cancer and ‘bothered’ by at least two of the three cluster symptoms) received usual care plus a multicomponent intervention delivered over two intervention training sessions and a follow-up telephone call or usual care only. Follow-up was for 12 weeks and end-points included: six numerical rating scales (NRS) for breathlessness severity; Dyspnoea-12; Manchester Cough in Lung Cancer scale (MCLS); FACT-Fatigue scale (FACT-F); Hospital Anxiety and Depression scale (HADS); Lung Cancer Symptom Scale (LCSS); and the EQ-5D-3L, collected at baseline, week-4 and week-12. Results: 107 patients were randomised over eight months; however six were removed from further analysis due to protocol violations (intervention group n=50 and control group n=51). Of the ineligible patients (n = 608), 29% reported either not experiencing two or more symptoms or not being ‘bothered’ by at least two symptoms. There was 29% drop-out by week four and by week 12 a further two patients in the control group were lost to follow-up. A sample size calculation indicated that 122 patients per arm would be needed to detect a clinically important difference in the main outcome for breathlessness, cough and fatigue. Conclusions: The study has provided evidence of the feasibility and acceptability of a new intervention in the lung cancer population, and warrants a fully powered trial before we reach any conclusions. The follow-on trial will test the hypothesis that the intervention improves symptom cluster of breathlessness, cough and fatigue better than usual care alone. Full economic evaluation will be conducted in the main trial.

AB - Background: Breathlessness, cough and fatigue are distressing symptoms for patients with lung cancer. There is evidence that these three symptoms form a discreet symptom cluster. This study aimed to feasibility test a new non-pharmacological intervention for the management of the Respiratory Distress Symptom Cluster (breathlessness-cough-fatigue) in lung cancer. Method: This was a multi-centre, randomised controlled non-blinded parallel group feasibility trial. Eligible patients (patients with primary lung cancer and ‘bothered’ by at least two of the three cluster symptoms) received usual care plus a multicomponent intervention delivered over two intervention training sessions and a follow-up telephone call or usual care only. Follow-up was for 12 weeks and end-points included: six numerical rating scales (NRS) for breathlessness severity; Dyspnoea-12; Manchester Cough in Lung Cancer scale (MCLS); FACT-Fatigue scale (FACT-F); Hospital Anxiety and Depression scale (HADS); Lung Cancer Symptom Scale (LCSS); and the EQ-5D-3L, collected at baseline, week-4 and week-12. Results: 107 patients were randomised over eight months; however six were removed from further analysis due to protocol violations (intervention group n=50 and control group n=51). Of the ineligible patients (n = 608), 29% reported either not experiencing two or more symptoms or not being ‘bothered’ by at least two symptoms. There was 29% drop-out by week four and by week 12 a further two patients in the control group were lost to follow-up. A sample size calculation indicated that 122 patients per arm would be needed to detect a clinically important difference in the main outcome for breathlessness, cough and fatigue. Conclusions: The study has provided evidence of the feasibility and acceptability of a new intervention in the lung cancer population, and warrants a fully powered trial before we reach any conclusions. The follow-on trial will test the hypothesis that the intervention improves symptom cluster of breathlessness, cough and fatigue better than usual care alone. Full economic evaluation will be conducted in the main trial.

KW - Breathlessness

KW - Cough

KW - Dyspnoea

KW - Fatigue

KW - Lung cancer

KW - Non-pharmacological intervention

KW - Respiratory symptoms

KW - Self-management

KW - Symptom cluster

KW - Symptoms

U2 - 10.1007/s00520-015-2810-x

DO - 10.1007/s00520-015-2810-x

M3 - Article

C2 - 26111954

VL - 23

SP - 3373

EP - 3384

JO - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

JF - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

SN - 0941-4355

IS - 11

ER -